[go: up one dir, main page]

WO2012018594A3 - Polysaccharides d'origine végétale pour l'administration de thérapies à base d'arn - Google Patents

Polysaccharides d'origine végétale pour l'administration de thérapies à base d'arn Download PDF

Info

Publication number
WO2012018594A3
WO2012018594A3 PCT/US2011/045239 US2011045239W WO2012018594A3 WO 2012018594 A3 WO2012018594 A3 WO 2012018594A3 US 2011045239 W US2011045239 W US 2011045239W WO 2012018594 A3 WO2012018594 A3 WO 2012018594A3
Authority
WO
WIPO (PCT)
Prior art keywords
rna
delivery
plant
based therapies
derived polysaccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/045239
Other languages
English (en)
Other versions
WO2012018594A2 (fr
Inventor
Alexzander A.A. Asea
Rajani Srinivasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Scott and White Health
Original Assignee
Scott and White Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott and White Healthcare filed Critical Scott and White Healthcare
Publication of WO2012018594A2 publication Critical patent/WO2012018594A2/fr
Publication of WO2012018594A3 publication Critical patent/WO2012018594A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés mettant en jeu des polysaccharides et des acides nucléiques. Dans des modes de réalisation particuliers, l'acide nucléique est un siARN dirigé contre une séquence codante de protéine de choc thermique de mammifère. Dans des modes de réalisation supplémentaires, le polysaccharide comprend du galactomannane ou de l'acide galacturonique.
PCT/US2011/045239 2010-07-26 2011-07-25 Polysaccharides d'origine végétale pour l'administration de thérapies à base d'arn Ceased WO2012018594A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36750710P 2010-07-26 2010-07-26
US61/367,507 2010-07-26
US201061424434P 2010-12-17 2010-12-17
US61/424,434 2010-12-17

Publications (2)

Publication Number Publication Date
WO2012018594A2 WO2012018594A2 (fr) 2012-02-09
WO2012018594A3 true WO2012018594A3 (fr) 2012-05-18

Family

ID=45559981

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045239 Ceased WO2012018594A2 (fr) 2010-07-26 2011-07-25 Polysaccharides d'origine végétale pour l'administration de thérapies à base d'arn

Country Status (1)

Country Link
WO (1) WO2012018594A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20060240092A1 (en) * 2005-04-01 2006-10-26 Kurt Breitenkamp Polymeric micelles for drug delivery
US20070213287A1 (en) * 2000-03-03 2007-09-13 Genetronics, Inc. Nucleic Acid Formulations for Gene Delivery and Methods of Use
US20090142391A1 (en) * 2007-08-14 2009-06-04 Mutz Mitchell W Conjugated RNAi Therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213287A1 (en) * 2000-03-03 2007-09-13 Genetronics, Inc. Nucleic Acid Formulations for Gene Delivery and Methods of Use
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20060240092A1 (en) * 2005-04-01 2006-10-26 Kurt Breitenkamp Polymeric micelles for drug delivery
US20090142391A1 (en) * 2007-08-14 2009-06-04 Mutz Mitchell W Conjugated RNAi Therapeutics

Also Published As

Publication number Publication date
WO2012018594A2 (fr) 2012-02-09

Similar Documents

Publication Publication Date Title
CA2873274C (fr) Administration pulmonaire d'un arn messager
MX2013008903A (es) Metodos de desarrollo de variantes de terpeno sintasa.
WO2014011465A3 (fr) Administration d'antigène ciblé à un aptamère
WO2012045082A3 (fr) Synthèse d'acides nucléiques et méthodes d'utilisation associées
WO2011063308A3 (fr) Variants de bêta-glucosidase à propriétés améliorées
WO2011005799A3 (fr) Molécules d'arn autorépliquantes et leurs utilisations
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
WO2013096709A3 (fr) Procédés d'augmentation de la viabilité ou de la longévité d'un organe ou d'un explant d'organe
PH12012501838A1 (en) Aptamers to ãŸ-ngf and their use in treating ãŸ-ngf mediated diseases and disorders
EA201390188A1 (ru) Реагирующий на стимулы тампон с высокой вязкостью
WO2009155594A3 (fr) Procédé de préparation de compositions adhésives à usage médical faisant appel à un seul additif utilisé comme agent épaississant et comme accélérateur
WO2009059284A3 (fr) Compositions de polysaccharides non anticoagulants
WO2012024526A3 (fr) Conjugués, particules, compositions et procédés associés
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
WO2012049083A3 (fr) Nouvelles fucosyltransférases et leurs applications
HK1219955A1 (zh) 含4'-硫代修饰的核苷酸的核糖核酸及相关方法
PL2539371T3 (pl) Produkty polisacharydowe o polepszonych właściwościach i przejrzystości w kompozycjach wodnych opartych na środkach powierzchniowo-czynnych i sposób wytwarzania
WO2010088565A8 (fr) Administration d'acide nucléique à l'aide de chitosanes modifiées
WO2010141471A3 (fr) Compositions pour l'administration d'acides nucléiques et procédés pour les utiliser
WO2010147888A3 (fr) Mousses polymères
WO2013013017A3 (fr) Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal
WO2010078036A3 (fr) Hydrogels biocompatibles à base de polysaccharides
WO2012154680A3 (fr) Composés β-glucane modifiés et dérivatisés, compositions, et procédés
WO2014111876A3 (fr) Modulation de la mitophagie et son utilisation
WO2012092382A3 (fr) Rôle du miarn dans la réponse immunitaire en cellules t

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815051

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815051

Country of ref document: EP

Kind code of ref document: A2